Saudi Central Bank Increases Stock Position in Johnson & Johnson $JNJ

Key Points

• Saudi Central Bank increased its Johnson & Johnson position by 35.7% in the second quarter, adding 79,673 shares to reach 302,628 shares valued at approximately $76.7 million.
• Johnson & Johnson reported quarterly revenue of $25.31 billion and adjusted EPS of $2.90, exceeding analyst expectations; management maintained fiscal 2026 EPS guidance of $11.60–$11.75 and pays a $5.36 annualized dividend.
• Investors are weighing potential catalysts—including a reported $20 billion sale of the DePuy Synthes orthopedics unit and strong RYBREVANT trial results—against risks such as a failed depression-drug trial, biosimilar competition and controversy surrounding 340B pricing requirements.

Saudi Central Bank lifted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 35.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 302,628 shares of the company's stock after purchasing an additional 79,673 shares during the period. Johnson & Johnson comprises about 1.0% of Saudi Central Bank's holdings, making the stock its 23rd largest position. Saudi Central Bank's holdings in Johnson & Johnson were worth $76,734,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Blueline Advisors LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $25,000. Outlook Capital Management LLC purchased a new position in shares of Johnson & Johnson during the second quarter worth approximately $28,000. MidAtlantic Capital Management Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $37,000. Matrix Trust Co increased its holdings in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after acquiring an additional 54 shares during the period. Finally, Hyposwiss Advisors SA purchased a new stake in Johnson & Johnson in the 4th quarter valued at $42,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J is reportedly in discussions with Apollo Global Management to sell its DePuy Synthes orthopedics business for approximately $20 billion. A transaction could unlock significant value, provide capital for debt reduction, buybacks or acquisitions, and sharpen the company’s focus on higher-growth businesses. However, DePuy Synthes generated $9.3 billion in sales last year, so investors will weigh proceeds against the loss of ongoing revenue. J&J in talks to sell DePuy Synthes to Apollo for $20 billion
• Positive Sentiment: Phase 3 PAPILLON results for RYBREVANT plus chemotherapy showed median overall survival of 34.3 months in patients with EGFR exon 20 insertion-positive non-small cell lung cancer. The durable benefit strengthens the commercial outlook for a key oncology product and supports J&J’s strategy of offsetting pressure from older medicines. RYBREVANT PAPILLON study results
• Positive Sentiment: Management is targeting double-digit growth despite anticipated biosimilar competition for STELARA, suggesting confidence in new product launches, oncology momentum and broader pharmaceutical diversification. Johnson & Johnson targets double-digit growth
• Neutral Sentiment: At the Morgan Stanley healthcare conference, J&J presented its business outlook and strategy; the available report provides no specific new guidance likely to materially change earnings expectations. Morgan Stanley healthcare conference transcript
• Negative Sentiment: Contineum Therapeutics said the mid-stage trial of JNJ-5120, or PIPE-307, failed to meet its primary objective in major depressive disorder. The failure removes or delays a potential pipeline opportunity, though the financial impact may be limited because the program is partnered. Contineum and J&J depression drug trial
• Negative Sentiment: J&J’s requirement that providers submit claims data to receive 340B discounts could generate pushback from hospitals and safety-net providers, increasing reputational, legal or policy risk around the company’s pricing practices. J&J 340B reporting requirement

Johnson & Johnson Stock Up 0.5%

Shares of Johnson & Johnson stock opened at $266.81 on Tuesday. Johnson & Johnson has a one year low of $173.33 and a one year high of $281.07. The company has a market cap of $642.99 billion, a P/E ratio of 30.92, a PEG ratio of 2.54 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a fifty day moving average of $263.18 and a two-hundred day moving average of $246.08.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion during the quarter, compared to analysts' expectations of $25.06 billion. During the same period last year, the firm earned $2.77 EPS. The company's quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson's payout ratio is 62.11%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares of the company's stock, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 87,569 shares of company stock valued at $23,064,544 over the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Citigroup upped their target price on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Argus set a $300.00 price target on Johnson & Johnson in a research report on Wednesday, July 29th. Morgan Stanley upped their price objective on Johnson & Johnson from $284.00 to $294.00 and gave the company an "overweight" rating in a research note on Thursday, July 16th. Freedom Capital raised Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Finally, Johnson Rice reiterated a "buy" rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $274.13.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.